Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Keytruda
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 01, 2020
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
